Design, Synthesis and Structure of Peptides and Proteins news

28 Mar 2017

Radio 5 (RNE) interviews Ernest Giralt, head of the Design, Synthesis and Structure of Peptides and Proteins Lab at IRB Barcelona, and Macarena Sánchez, research associate in the same Lab, about IRB Barcelona’s research to tackle Friedreich’s ataxia. In the interview, Giralt explains that Friedreich’s ataxia is a hereditary degenerative disease that normally appears between the ages of 5 and 25, for which there is currently no cure.

IRB Barcelona’s project, supported by the patient and family association, the Babel Family, and the Asociación Granadina de la ataxia de Friedreich, aims to complete a step necessary to move towards a future frataxin replacement therapy for...

<p>Scheme of therapeutic concept designed by IRB Barcelona. The protein frataxina binds to peptide shuttle (blue), allowing the protein to cross the blood brain barrier and reach the brain (IRB Barcelona)</p>
14 Mar 2017

IRB Barcelona starts a project with the long-term goal to achieve an injectable frataxin treatment able to reach the brain.

Frataxin is the protein that is reduced in those affected by this rare and degenerative disease, which has no cure.

The patients’ associations Babel Family and ASOGAF in Granada provide the funding for the initial 18 months of this challenge.

<p>Mice neurons with the Frataxin gene transfered. In yellow, localization of the frataxin protein in neurons (Picture: Díaz-Nido lab)</p>
14 Mar 2017

Several media have echoed the research project on Friedreich’s Ataxia at IRB Barcelona, funded by the associations of patients and families called the Babel Family and the Asociación Granadina de la Ataxia de Friedreich (ASOGAF), for the initial 18 months. 

The project aims to develop an injectable frataxin treatment that can reach the brain. Frataxin is the protein that is reduced in those affected by this rare and degenerative disease, which has no cure.

More information about the project

Media mentions

Link to...

10 Mar 2017

The Generalitat’s (Catalan Government) Universities and Research website has echoed on the research performed by scientists at IRB Barcelona and the UB, namely a shuttle produced from a peptide present in bee venom and capable of transporting molecules into the brain.

The research results arose from the Benjamí Oller's PhD thesis, done in Professor Ernest Giralt's Lab at IRB Barcelona and defended in 2015. In January 2016, he started his postdoctoral training in Cambridge, UK. 

Link to Universities and...

<p>Cristina Fuster didn't miss out on the opportunity to stay in one of the famous capsule hotels while in Japan</p>
7 Feb 2017

Cristina Fuster (Girona, 1989) is the first IRB Barcelona student to participate in the academic exchange programme recently signed with the Graduate School of Pharmaceutical Sciences of the Tohoku University in North East Japan.

<p>Iproteos is currently performing the regulatory preclinical phase of its drug candidate for CIAS treatment.</p>
19 Dec 2016

Compound IPR19, a drug to stop the progression and reverse the cognitive deficits associated with schizophrenia.

4 Dec 2016

The newspaper “El Periódico” interviews Meritxell Teixidó, associate researcher at IRB Barcelona, and Benjamí Oller Salvia, former PhD student at the same institute, about their research performed in the Design, Synthesis and Structure of Peptides and Proteins Lab. In the article, they talk about their discovery, namely a shuttle capable of transporting molecules into the brain.

Link to El Periódico 

<p>Salva (left) and Yoran are involved in an ambitious project to strengthen the connection between science, economy, politics and society</p>
23 Nov 2016


The youngest and most restless scientists often keep themselves busy with projects outside their labs. One such project is the "Scientists Dating Forum," which has attracted the interest of several PhD students at IRB Barcelona.

In vivo met Yoran Beldengrün, a Swiss PhD student at the Institute for Advanced Chemistry of Catalonia – CSIC, who is behind the initiative in which more than 50 people—including scientists, journalists, artists, and entrepreneurs—have been actively involved since the beginning of the year.

“I noticed that many people were...

<p>Teresa Tarragó, CEO and co-founder of Iproteos</p>
25 Oct 2016

The biotech will set aside this injection of capital –led by Caixa Capital Risc- to complete the preclinical phase in order to start Human Phase I trials of its compound to the treatment of Cognitive Impairment Associated with Schizophrenia. The drug is one of the few under development worldwide to halt the progression and reverse the symptoms of this condition.

The drug is a first-in-class for the treatment of Cognitive Impairment Associated with Schizophrenia  (CIAS). The compound has been developed using their proprietary IPROTech, a cutting-edge platform the fast and cost-effectively obtaining of innovative drugs.  

Iproteos, settled at the Parc Cientific de Barcelona, is a spin-off created in 2011 by two Catalan leading scientists in the field of therapeutic peptides, Teresa Tarragó and Ernest Giralt, based on the technology transfer from IRB Barcelona and the University of Barcelona.

28 Sep 2016

Back from a very rewarding stay in Yale, Pol already has new ideas in mind to overcome the barrier that protects the brain and makes it so difficult to design drugs to cure neurological diseases.